251 related articles for article (PubMed ID: 34895181)
1. Using the Goal Attainment Scale adapted for depression to better understand treatment outcomes in patients with major depressive disorder switching to vortioxetine: a phase 4, single-arm, open-label, multicenter study.
McCue M; Sarkey S; Eramo A; François C; Parikh SV
BMC Psychiatry; 2021 Dec; 21(1):622. PubMed ID: 34895181
[TBL] [Abstract][Full Text] [Related]
2. Goal Attainment Scaling for Depression: Validation of the Japanese GAS-D Tool in Patients with Major Depressive Disorder.
Kato M; Kikuchi T; Watanabe K; Sumiyoshi T; Moriguchi Y; Oudin Åström D; Christensen MC
Neuropsychiatr Dis Treat; 2024; 20():49-60. PubMed ID: 38239870
[TBL] [Abstract][Full Text] [Related]
3. Design of a real-world, prospective, longitudinal, observational study to compare vortioxetine with other standard of care antidepressant treatments in patients with major depressive disorder: a PatientsLikeMe survey.
Raveendran S; Singh D; Burke MC; McAuliffe-Fogarty AH; Parikh SV; McIntyre RS; Roy A; Martin M; Chrones L; Opler MGA; Blair C; McCue M
BMC Psychiatry; 2023 Jun; 23(1):464. PubMed ID: 37365543
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness of vortioxetine in patients with major depressive disorder and co-morbid generalized anxiety disorder in routine clinical practice: A subgroup analysis of the RELIEVE study.
Almeida SS; Christensen MC; Simonsen K; Adair M
J Psychopharmacol; 2023 Mar; 37(3):279-288. PubMed ID: 36377523
[TBL] [Abstract][Full Text] [Related]
5. Vortioxetine improves symptomatic and functional outcomes in major depressive disorder: A novel dual outcome measure in depressive disorders.
Christensen MC; Loft H; McIntyre RS
J Affect Disord; 2018 Feb; 227():787-794. PubMed ID: 29689693
[TBL] [Abstract][Full Text] [Related]
6. Randomized, double-blind, placebo-controlled study to assess the efficacy and safety of vortioxetine in Japanese patients with major depressive disorder.
Inoue T; Sasai K; Kitagawa T; Nishimura A; Inada I
Psychiatry Clin Neurosci; 2020 Feb; 74(2):140-148. PubMed ID: 31725942
[TBL] [Abstract][Full Text] [Related]
7. Safety and tolerability of vortioxetine (15 and 20 mg) in patients with major depressive disorder: results of an open-label, flexible-dose, 52-week extension study.
Jacobsen PL; Harper L; Chrones L; Chan S; Mahableshwarkar AR
Int Clin Psychopharmacol; 2015 Sep; 30(5):255-64. PubMed ID: 26020712
[TBL] [Abstract][Full Text] [Related]
8. Anti-inflammatory treatment of depression: study protocol for a randomised controlled trial of vortioxetine augmented with celecoxib or placebo.
Fourrier C; Sampson E; Mills NT; Baune BT
Trials; 2018 Aug; 19(1):447. PubMed ID: 30126458
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness of vortioxetine in patients with major depressive disorder comorbid with generalized anxiety disorder: Results of the RECONNECT study.
Christensen MC; Schmidt S; Grande I
J Psychopharmacol; 2022 May; 36(5):566-577. PubMed ID: 35499104
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness of vortioxetine in patients with major depressive disorder and early-stage dementia: The MEMORY study.
Christensen MC; Schmidt SN; Grande I
J Affect Disord; 2023 Oct; 338():423-431. PubMed ID: 37315590
[TBL] [Abstract][Full Text] [Related]
11. A randomized, double-blind trial of 2.5 mg and 5 mg vortioxetine (Lu AA21004) versus placebo for 8 weeks in adults with major depressive disorder.
Mahableshwarkar AR; Jacobsen PL; Chen Y
Curr Med Res Opin; 2013 Mar; 29(3):217-26. PubMed ID: 23252878
[TBL] [Abstract][Full Text] [Related]
12. Long-term functioning outcomes are predicted by cognitive symptoms in working patients with major depressive disorder treated with vortioxetine: results from the AtWoRC study.
Chokka P; Bougie J; Proulx J; Tvistholm AH; Ettrup A
CNS Spectr; 2019 Dec; 24(6):616-627. PubMed ID: 30802419
[TBL] [Abstract][Full Text] [Related]
13. A randomized, double-blind, placebo-controlled 6-wk trial of the efficacy and tolerability of 5 mg vortioxetine in adults with major depressive disorder.
Jain R; Mahableshwarkar AR; Jacobsen PL; Chen Y; Thase ME
Int J Neuropsychopharmacol; 2013 Mar; 16(2):313-21. PubMed ID: 22963932
[TBL] [Abstract][Full Text] [Related]
14. Goal setting and goal attainment in patients with major depressive disorder: a narrative review on shared decision making in clinical practice.
Baldwin DS; Adair M; Micheelsen A; Åstrøm DO; Reines EH
Curr Med Res Opin; 2024 Mar; 40(3):483-491. PubMed ID: 38294154
[TBL] [Abstract][Full Text] [Related]
15. Real-world clinical outcomes and treatment patterns in patients with MDD treated with vortioxetine: a retrospective study.
McDaniel BT; Cornet V; Carroll J; Chrones L; Chudzik J; Cochran J; Guha S; Lawrence DF; McCue M; Sarkey S; Lorenz B; Fawver J
BMC Psychiatry; 2023 Dec; 23(1):938. PubMed ID: 38093196
[TBL] [Abstract][Full Text] [Related]
16. Safety, tolerability, and efficacy of vortioxetine (Lu AA21004) in major depressive disorder: results of an open-label, flexible-dose, 52-week extension study.
Alam MY; Jacobsen PL; Chen Y; Serenko M; Mahableshwarkar AR
Int Clin Psychopharmacol; 2014 Jan; 29(1):36-44. PubMed ID: 24169027
[TBL] [Abstract][Full Text] [Related]
17. A 6-Month Open-Label Study of Vortioxetine among Cancer Patients with Major Depressive Disorder (MDD).
Ng CG; Abousheishaa AA; Low SY; Zainal NZ; Thong KS; Awaluddin AB; Loo TH; Yacob SB; Nik Jaafar NR; Abdul Taib NIA; Mohamad Kamal NAB; Ismail F; Zamaniah Wi W
Asian Pac J Cancer Prev; 2023 Aug; 24(8):2583-2591. PubMed ID: 37642043
[TBL] [Abstract][Full Text] [Related]
18. A novel study design for investigating relapse prevention in major depressive disorder: Preliminary data from the open-label period of a phase 4 vortioxetine study.
Jacobsen P; Zhong W; Xu R; Nomikos G
J Affect Disord; 2020 Apr; 266():173-181. PubMed ID: 32056873
[TBL] [Abstract][Full Text] [Related]
19. The effects of vortioxetine on cognitive performance in working patients with major depressive disorder: A short-term, randomized, double-blind, exploratory study.
Baune BT; Sluth LB; Olsen CK
J Affect Disord; 2018 Mar; 229():421-428. PubMed ID: 29331703
[TBL] [Abstract][Full Text] [Related]
20. A Randomized, Placebo-Controlled, Active-Reference, Double-Blind, Flexible-Dose Study of the Efficacy of Vortioxetine on Cognitive Function in Major Depressive Disorder.
Mahableshwarkar AR; Zajecka J; Jacobson W; Chen Y; Keefe RS
Neuropsychopharmacology; 2015 Jul; 40(8):2025-37. PubMed ID: 25687662
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
